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Abstract
Background and Objective The inhibition of fatty acid
amide hydrolase 1 (FAAH) has been proposed as a novel
mechanism for treating pain syndromes by increasing the
levels of endogenous cannabinoids (ECs). This study
describes the safety, tolerability, pharmacokinetics and
pharmacodynamics of V158866, a reversible FAAH inhi-
bitor, after first administration to man.
Methods 51 healthy male subjects were recruited into this
double-blind, randomised, placebo-controlled, adaptive dose,
phase I single (Part A) and repeated ascending dose (Part B)
study. The primary outcome was the safety and tolerability of
V158866. Secondary outcomes were (1) pharmacokinetics of
V158866 and (2) pharmacodynamics ofV158866, as assessed
by changes in plasma EC concentrations.
Results Single oral doses of 5–300 mg and repeated oral
doses of 50–500 mg were evaluated. V158866 was well
tolerated, with no apparent treatment-related effects on
laboratory variables. V158866 was rapidly absorbed with a
mean terminal elimination half-life of 9.6–18.3 h (Day 7;
Part B). V158866 reached steady state within 2–3 days of
administration, with an accumulation ratio, based on
AUC0–24h, of approximately 2 on Day 7. V158866 showed
a linear relationship between dose and AUC across the
entire dose range. V158866 caused reversible, dose-related
increases in plasma ECs. At hemi-equilibrium, there was a
sigmoidal maximum effect relationship between plasma
V158866 concentrations and changes in plasma ECs.
Conclusions V158866 is well tolerated, with linear
pharmacokinetics suitable for once-daily administration,
and reversible effects on plasma ECs. Maximum increases
in plasma ECs occur with V158866 doses of
300–500 mg/day.
Key Points
Inhibition of fatty acid amide hydrolase 1 (FAAH)
has been proposed as a novel mechanism for treating
pain syndromes, by increasing the levels of
endogenous cannabinoids. This approach has the
potential to provide the pain relief of cannabis
without the associated side effects.
This is a first in-man study of the FAAH inhibitor
V158866. After oral administration, V158866 is well
tolerated with predictable pharmacokinetics
suitable for once-daily administration.
V158866 causes dose-dependent increases in plasma
endocannabinoids, with maximum changes at doses
of 300–500 mg/day.
Further clinical trials in patients with syndromes
such as neuropathic pain are needed to establish
safety and efficacy.
Electronic supplementary material The online version of this
article (doi:10.1007/s40268-016-0127-y) contains supplementary
material, which is available to authorized users.
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1 Introduction
The medicinal benefits and psychotropic disadvantages of
cannabis (Cannabis sativa) have been recognized for cen-
turies [1]. Cannabinoids, the pharmacologically active
components of cannabis, act in vertebrates primarily on the
G-protein-coupled post-synaptic receptors CB1 and CB2.
CB1 receptors are predominantly located in the central
nervous system (CNS), and additionally in tissues includ-
ing the liver, adipose tissue, pancreas, gut, genital tract and
muscle. Agonism typically causes cognitive impairment,
hypolocomotion, hyperphagia, hypothermia, anticonvul-
sant activity and analgesia. Endogenous ligands at the CB1
and CB2 receptors include the endocannabinoids, anan-
damide (N-arachidonyl ethanolamide, AEA) and 2-arachi-
donoyl-glycerol. Those receptors are also activated by D9-
tetrahydrocannabinol (THC), the principal active substance
in cannabis [2]. THC and other direct CB1 agonists (e.g.
dronabinol, nabilone) have a range of clinical benefits,
including analgesia (particularly for neuropathic pain [3]),
anxiolysis, antidepressant and antiemetic properties, appe-
tite stimulation and muscle relaxation [4, 5]. However,
their clinical utility is limited by multiple side effects, such
as impairment of cognition and motor control [6].
Fatty acid amide hydrolase (FAAH) is an integral
membrane enzyme that hydrolyses the endocannabinoid,
AEA, and related signalling lipids [7]. In humans, FAAH
exists in two forms (FAAH1 and FAAH2 [8]). FAAH-
knockout (KO) mice display analgesia and anti-inflamma-
tory phenotypes without disruption of motility, cognition or
body temperature [9, 10], effects which are emulated by
pharmacologic inhibition of FAAH [11, 12]. That has led
to the hypothesis that FAAH inhibitors may be effective for
the treatment of pain without the side effects associated
with direct-acting cannabinoid agonists [13].
Several FAAH inhibitors are reported to be in devel-
opment [14], but to our knowledge the only published
clinical studies use the irreversible, urea-based inhibitor
PF-04457845 [15]. PF-04457845 is well tolerated at doses
that cause maximal inhibition of FAAH and elevation of
plasma endocannabinoids [16] and was progressed into a
phase II study in osteoarthritic pain where it was found to
be without effect [17]. Whilst there has been some debate
about the trial design [18], the lack of effect of PF-
04457845 in osteoarthritic pain argues for a more detailed
review of the rationale for phase II clinical trials of FAAH
inhibitors, with particular reference to the effects of
cannabinoid agonists in patients with any particular pain
state [19]. Indeed, as the beneficial clinical effects of
cannabinoids are often due to their effects on comorbidities
(rather than the perception of noxious stimuli per se),
FAAH inhibition may be more appropriate for the
treatment of pain syndromes such as neuropathic pain [3]
and multiple sclerosis [5].
This is a report of the first clinical study of the azetidine
analogue V158866, a potent, reversible, orally available
FAAH inhibitor with efficacy in rodent models of inflam-
matory pain [20]. The primary objective of the study was to
evaluate the safety and tolerability of single and repeated
doses of V158866 in healthy male subjects. The secondary
objectives of the study were to assess the pharmacokinetics
and pharmacodynamics of V158866.
2 Methods
This was a single centre, phase I, double-blind, ran-
domised, placebo-controlled, adaptive dose, single (Part A)
and repeated ascending (Part B) dose study designed to
compare the safety, tolerability, pharmacokinetics (PK)
and pharmacodynamics (PD) of V158866 with placebo.
The trial was conducted at Hammersmith Medicines
Research (HMR), London, UK.
2.1 Subjects
Eligibility for this study required that subjects be healthy
men aged 18–45 years, with a body mass index between 19
and 30 kg/m2. Subjects had to be able to provide a semen
sample and willing to use an effective method of contra-
ception for the duration of the study and for 4 months after
the last dose of study medication. All subjects had to be
willing and able to comply with the requirements of the
entire study, and provided written informed consent before
participating.
Exclusion criteria included prior vasectomy, or the
intention to father a child within 4 months of study con-
clusion, multiple drug allergies or allergy to any of the
components of V158866 study medication and laboratory,
electrocardiography (ECG) or other abnormalities that
might increase the risk to the subject or interfere with the
interpretation of study results. The remaining, standardized
criteria related to cigarette smoking, alcohol consumption,
recreational and therapeutic drug use (except paracetamol),
and seropositivity for hepatitis B, hepatitis C or HIV.
Subjects were not permitted to consume caffeine-contain-
ing food or drinks, grapefruit products, or alcohol for 24 h
before or during each admission.
2.2 Study Design
The study was conducted between February and July 2011
in two parts, with Part B commencing after completion of
Part A.
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Part A Single ascending dose, partial cross over: sub-
jects in two cohorts of nine (six active and three placebo at
each dose level) each received two single oral doses of
V158866 and one dose of matching placebo in separate
study periods, with a washout of at least 7 days between
successive doses. Subjects participated in Part A for about
9 weeks.
Part B Repeated ascending dose, parallel group: sub-
jects in four cohorts of eight (six active and two placebo at
each dose level) each received once-daily doses of
V158866 or placebo for 7 days. Subjects participated in
Part B for about 6 weeks.
For each cohort, eligible subjects were assigned a
sequential randomisation number on admission and treat-
ment was allocated according to a pre-defined randomisa-
tion code generated by the Statistical Analysis System
(SAS) programmer at HMR. Randomisation lists were not
available to personnel at the study centre (with the
exception of the Pharmacist and delegated study staff
involved in dispensing), the Vernalis monitor, project
statisticians or any of the project team at Vernalis until
after database lock.
During Part A, between Part A and Part B, and during
Part B of the study, the safety, PK and PD data from the
previous dose cohort were reviewed in a blinded manner
before recommendations for the next dose level were made.
2.3 Dose Selection
In non-clinical toxicology studies, the no observable
adverse event level (NOAEL) dose of V158866 in rat and
dog was associated with area under the concentration–time
curve from time 0 to 24 h (AUC0–24h) values of 13 and
87 lgh/mL, respectively. Using a safety factor of 100 and
comparison with the NOAEL on a mg/kg basis, or a safety
factor of 10 and two different methods for predicting human
exposure (PK modelling, and body surface area-corrected
human equivalent dose), the estimated safe starting dose
range based on the rat or dog was 2–7 mg and 25–150 mg,
respectively. The starting dose of V158866 chosen in Part A
of the study was 5 mg. As toxicological findings in the rat
included minor reversible changes in the male reproductive
tract, safety assessments included routine seminology. The
doses selected for the remainder of the study were chosen
on the basis of (blinded) emerging safety, PK and PD data to
determine a safe and tolerable dose of V158866, maximum
inhibition of FAAH and significant increases in plasma
endocannabinoid concentrations.
2.4 Safety
Safety was assessed by monitoring adverse events (AEs)
(coded using MedDRA version 14.1), recording vital signs
(supine/semi-recumbent and standing blood pressure and
pulse; respiratory rate and oral temperature), 12-lead
ECGs, physical examination, body weight, laboratory
safety tests (haematology, biochemistry, endocrine markers
and urinalysis) and telemetry for cardiac rhythm monitor-
ing. Semen quality was assessed at baseline and follow up.
2.5 Bioanalytical Methods
Venous blood samples were collected from each subject
into lithium-heparinised tubes at intervals from pre-dose
until 72 h (Part A) or 240 h (Part B) post-dose. Samples
were centrifuged within 60 min of collection and the
resultant plasma split into aliquots (for V158866 and
endocannabinoid determination) and stored at -20 C or
below until assay.
Urine was collected and pooled into 1-L polypropylene
containers and stored at 4 C for the duration of each
specified collection interval (12 or 24 h). Duplicate 4.5 mL
aliquots of urine were then stored at -20 C until assay.
V158866 in human plasma and urine samples was
assayed using a validated liquid chromatography with a
tandem mass spectrometric (LC–MS/MS) method. Plasma
samples were analysed for AEA, N-linoleoyl ethanolamide
(LEA), N-oleoyl ethanolamide (OEA) and N-palmitoyl
ethanolamide (PEA) using a validated LC–MS/MS
method. Blood FAAH activity was determined by the
method of Ahn et al. [21]. For all assays, samples in which
the concentration of test agent exceeded the calibration
range were diluted with blank assay matrix and re-anal-
ysed. The calibration ranges, Lower Limit of Quantitation
(LLoQ) and accuracy values (based upon the calibration
standards across the range) for each assay are detailed in
the electronic supplementary material (Table ESM1).
2.6 Test Product
V158866 was presented as a liquid suspension (2 mg/mL
or 20 mg/mL) in OraBlendTM suspending vehicle con-
taining 5 % weight/volume (w/v) polyvinylpyrrolidone
(PVP, Kollidon K90) for oral administration, taken with
180 mL of water. Subjects were fasted for 10 h before each
dose. Six dose levels (5, 15, 30, 70, 150 and 300 mg) of
V158866 were administered in Part A as single doses. Four
dose levels (50, 150, 300 and 500 mg) of V158866 were
administered in Part B as daily doses for 7 days. Placebo
was identical to the test product without the active
ingredient.
2.7 Data Analysis and Statistics
No formal sample size calculation was performed as this
was an exploratory study. Sample sizes of 6 V158866-
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treated subjects per dose level and 18 (Part A) or 8 (Part B)
in the pooled placebo groups were considered sufficient to
achieve the objectives of the study. No formal hypothesis
testing was conducted.
Descriptive statistics [number of observations and mean
and coefficient of variation (CV) or median and range
according to distribution] are presented for continuous PK
and PD variables, with 95 % confidence intervals (CI)
where appropriate. Categorical data are summarised in
frequency tables.
All available data were used in the PK and PD analyses,
other than that from subjects with significant protocol
deviations that might have invalidated or biased the results.
To generate meaningful descriptive statistics for groups of
analytical samples where the estimate of a test agent in
some samples was below the LLoQ, a value equal to zero
or LLoQ/2 was used.
The following non-compartmental PK parameters were
calculated using WinNonlin version 6.2; maximum
observed concentration (Cmax), time to Cmax (Tmax), ter-
minal phase apparent elimination rate constant (kz), ter-
minal elimination half-life (t), area under the
concentration-time curve from time 0 to 24 h (AUC0–24h),
from time zero to last measured value (AUClast), from time
zero extrapolated to infinity (AUCinf) and concentration
observed 24 h post-dose on each day of Part B (Ctrough).
AUC and Cmax were tested for dose proportionality by
regression analysis of the log-transformed parameter versus
log-transformed dose, with dose as a fixed effect and
subject as a random effect. The slope, b, of this model was
estimated with 90 % CI (bL - bU) and used to estimate the
fold-increase in systemic exposure for a doubling in dose
(2b) with 90 % CI (2bL - 2bU). The CI of the slope, b,
was compared with the limits 1.6 to 2.5 (i.e. double the
standard equivalence limits of 0.8 to 1.25) for both AUCinf
and Cmax.
Comparisons of the single dose PK parameters (Day 1)
and those at the end of the repeated dose period (Day 7)
were made using a mixed effects model on log trans-
formed AUC0–24h and Cmax including day and dose
(classification factor) as fixed effects and subject as a
random effect. The day-by-dose interaction term was also
investigated. This model was used to estimate the accu-
mulation ratio (Day 7/Day 1) with 95 % CIs (from the
back-transformed mean differences). The time to achieve
steady state was explored graphically by plotting Ctrough
values against study day. Concentration-response analysis
was performed in Origin v8.1 using a non-linear curve fit
maximum effect (Emax) model where b was fixed at the
baseline plasma concentration for each endogenous




An overall summary of subject demographics is provided
in the electronic supplementary material (Table ESM2).
There were only minor differences between Parts of the
study or between dose groups.
3.2 Safety and Tolerability
Adverse events In total, 19 subjects were treated in Part A.
One subject discontinued after the first dose (5 mg) owing
to inadequate venous access. All remaining subjects each
received two single doses of V158866 and one of placebo
in separate treatment periods. All 32 subjects enrolled in
Part B completed the study. The number of subjects
experiencing at least one treatment-emergent adverse event
(TEAE), the severity of TEAEs and their possible rela-
tionship to study medication are summarised in Table 1.
V158866 was generally well tolerated with very few,
mostly mild, TEAEs reported. There were no severe
TEAEs, serious adverse events (SAEs) or TEAEs leading
to treatment withdrawal. The frequency of TEAEs was
generally similar across dose groups except for the highest
repeated dose (500 mg daily) group, in which there were
more overall, treatment-related and moderate TEAEs.
The most commonly reported treatment-related TEAEs
were nervous system disorders (headache, dizziness and
somnolence; Table 2). Events of that nature are consistent
with CNS-active drugs but are also commonly reported
after placebo in healthy volunteer studies. Overall, 13 were
considered possibly related to study treatment.
TEAEs such as dizziness and orthostatic hypotension
were reported mainly in the highest dose group (500 mg
daily, Part B). Other TEAEs were generally consistent with
those expected in a phase I trial or were single events
showing no apparent trend.
Other findings related to safety: there were no apparent
treatment- or dose-related effects of V158866 on routine
laboratory safety tests, vital signs, ECG, telemetry or
physical examination. Although seminology data were
highly variable both within and between subjects, there was
no apparent effect of V158866 on any seminology variable
(sperm count, semen volume, motility, liquefaction or
inflammatory cells).
3.3 Pharmacokinetics
Part A (single dose PK) The pharmacokinetic profile from
19 subjects [age range 19–42 years; mean weight ± stan-
dard error of the mean (SEM) 78.7 ± 2.8 kg] is presented;
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one subject discontinued after the first dose (5 mg) after
difficulty with venous access, and was replaced. V158866
was rapidly absorbed (median Tmax 1.5–2.5 h) with dose-
related increases in Cmax and a multiphasic decline in
plasma concentrations with mean terminal elimination
half-lives in the range 5.4–11.2 h. A tendency for the
plasma concentration of V158866 to increase between
18 and 24 h after administration was noted. Non-com-
partmental PK parameters are summarised in Table 3, and
mean plasma concentrations are shown in Fig. 1a.
There was clear dose proportionality for AUCinf after
single doses of V158866, with a 2.0-fold increase in
AUCinf (90 % CI 1.9–2.1) for a doubling of V158866
(Fig. 1b) as tested using the power model (described in
Sect. 2.7). The increase in Cmax was somewhat less than
dose proportional, with a 1.7-fold increase (90 % CI
1.7–1.8) for each doubling of V158866 dose (electronic
supplementary material; Fig. ESM3).
Little urinary excretion of V158866 was observed
(proportion of dose excreted in urine \0.3 %). As no
human metabolites of V158866 were identified in vitro,
and V158866 appeared to have relatively low plasma
clearance in this study, plasma and urine samples were not
analysed for metabolites.
Part B (repeated dose PK) The data from all 24
V158866-treated subjects (age range 19–42 years; mean
weight ± SEM 76.6 ± 1.5 kg) are presented. The plasma
profiles at Day 1 and Day 7 were generally similar to that
in Part A, with concentrations peaking quickly and
decreasing thereafter. The tendency for concentrations to
increase at 18–24 h was more apparent at Day 7 than Day
1. Non-compartmental PK on Day 1 and Day 7 are sum-
marised in Table 4, and mean plasma concentrations are
shown in Fig. 2.
There is approximately twofold accumulation of
V158866 after 7 days of administration at 150 mg once
daily and above. The calculated accumulation ratio
between Days 1 and 7 for 150 mg/day V158866 and above
ranged from 1.5 (95 % CI 1.2–2.0) to 1.8 (95 % CI
1.4–2.3) for Cmax and from 1.9 (95 % CI 1.6–2.3) to 2.8
(95 % CI 2.3–3.4) for AUC0–24h. Dose proportionality was
demonstrated for AUC0–24h on Day 7 with a 2.0-fold
Table 1 Summary of treatment-emergent adverse events (TEAEs)
Part A Placebo Dose V158866
5 mg 15 mg 30 mg 70 mg 150 mg 300 mg
n 18 7 6 6 6 6 6
Subjects with C1 TEAE 7 6 2 3 2 2 2
Mild (moderate) TEAEs 7 (1) 4 (2) 1 (1) 2 (1) 2 2 2 (1)
Treatment-related TEAEs 1 0 0 1 1 1 2
Part B Placebo Daily dose V158866
50 mg 150 mg 300 mg 500 mg
n 8 6 6 6 6
Subjects with C1 TEAE 3 3 2 3 6
Mild (moderate) TEAEs 2 (1) 2 (1) 2 2 (1) 5 (3)
Treatment-related TEAEs 1 3 1 2 3
Data are presented as number of subjects in each category
A TEAE was defined as an AE that started or increased in severity after the first dose of study medication up until the post-study visit
Treatment-related TEAEs were those with a possible relationship to study medication
Table 2 System organ class of treatment-related treatment-emergent adverse events (TEAEs) reported by C2 subjects in Part B of the study
System organ class Preferred term Placebo (n = 8) Daily dose V158866
50 mg (n = 6) 150 mg (n = 6) 300 mg (n = 6) 500 mg (n = 6)
Nervous system Headache 2 1 1
Dizziness 1 1
Somnolence 1 1
General Fatigue 1 1 1
Data are presented as number of subjects in each category
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increase (90 % CI 1.8–2.2) for a doubling dose as tested
using the power model (described in Sect. 2.7). The
increase in Cmax on Day 7 was somewhat less than dose
proportional, with a 1.7-fold increase (90 % CI 1.5–1.8) for
each doubling dose. Dose proportionality was not observed
on Day 1 for either Cmax or AUC0–24h as subsequent doses
prevented estimation of the terminal half-life. Steady state
Ctrough values appeared to be reached within 2–3 days post-
dose (Fig. 2).
Based on the low urinary excretion of V158866
observed in Part A, urine samples from Part B were not
analysed.
3.4 Pharmacodynamics
Part A (single dose PD) V158866 appeared to cause
maximal inhibition of blood FAAH activity at doses
C30 mg. However, FAAH activity data were imprecise, so
were unsuitable for more detailed PD analysis and are not
reported here.
V158866 caused dose-related increases in plasma AEA,
with measurable changes after the 5-mg dose (Fig. 3). EC
changes followed the plasma V158866 concentration, with
a time lag of about 2 h between maximum PK and PD
responses, and a return to baseline at 72 h post-dose.
V158866 caused similar changes in plasma OEA and PEA
concentrations, but the LEA response was biphasic with a
second peak at 12 h post-dose (electronic supplementary
material; Fig. ESM4). Whilst the PD effects of V158866
were clearly reversible, there was a lag between maximum
PK and PD responses such that when the relationship
between mean plasma V158866 and AEA concentrations
was plotted in time order, a characteristic counter-
clockwise hysteresis loop was observed (electronic sup-
plementary material; Fig. ESM5). Hysteresis was also seen
for OEA and PEA, but not LEA, which was complicated by
the biphasic PD response (data not shown).
Part B (repeated dose PD) As in Part A of the study,
V158866 caused dose-related increases in plasma EC
concentrations on both Day 1 and Day 7. EC changes
followed the plasma V158866 concentration, with a time
lag of about 2 h between maximum PK and PD responses,
and a return to baseline after Day 7 by 72 h post-dose.
During the repeated dose phase of Part B, steady state
(Ctrough) plasma ECs were achieved within 2–3 days post-
dose and were sustained until Day 8. Plasma AEA changes
are shown in Fig. 4; OEA and PEA showed qualitatively
similar responses. The biphasic LEA response observed in
Part A was again observed on Days 1 and 7 of Part B
(electronic supplementary material; Fig. ESM6, ESM7 and
ESM8).
A comparison of the Ctrough plasma concentrations of
V158866 with the corresponding plasma EC concentration
allowed a concentration–response curve to be generated for
each EC at hemi-equilibrium. This relationship (which is
best described by an Emax model) is shown in Fig. 5:
V158866 caused concentration-dependent increases in
plasma AEA, LEA, OEA and PEA concentrations, up to a
maximum of approximately 3, 4, 8 and 5 ng/mL, respec-
tively. Whilst the mid-point locations of the concentration–
response curves vary somewhat (potency order;
PEA[OEA[AEA = LEA), this analysis indicated that
maximum increases in AEA, OEA and PEA occur at
plasma V158866 concentrations of around 300 ng/mL or
greater, which can be achieved with oral V158866 doses of
300–500 mg/day.
Table 3 Summary of V158866 pharmacokinetics following single oral doses (Part A)
Parameter V158866
5 mg (n = 6–7) 15 mg (n = 6) 30 mg (n = 6) 70 mg (n = 6) 150 mg (n = 6) 300 mg (n = 6)





























































Data are presented as geometric mean (geometric CV) and range unless specified otherwise
kz terminal phase apparent elimination rate constant, AUCinf area under the concentration–time curve from time extrapolated to infinity, Cmax
maximum concentration, t half-life, Tmax time to maximum concentration
a Tmax is presented as median and range
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4 Discussion
This paper details the first in-human study of V158866, a
potent, novel, reversible FAAH inhibitor. V158866 was
well tolerated after single oral doses of 5–300 mg, and
repeated oral doses of 50–500 mg for up to 7 days.
Treatment-emergent adverse events for V158866 after
single and repeated doses were mostly mild in severity and
similar to those reported for placebo, except perhaps at the
highest repeated dose (500 mg daily). The most commonly
reported adverse events were nervous system disorders, as
might be expected for a CNS-active drug, and symptoms
such as dizziness and orthostatic hypotension might have
been treatment-related. This bland tolerability profile is
consistent with both the phenotype of the FAAH KO
mouse [9] and with previous clinical reports of the effects
of FAAH inhibition [16]. V158866 had no effect on vital
signs, ECG, routine laboratory safety tests or on any
seminology variable.
After single oral doses, the pharmacokinetics of
V158866 were predictable, with rapid absorption followed
by elimination with a half-life in the range of 5.4–11.2 h.
Fig. 1 V158866 plasma
exposure after single oral dose
administration (Part A): mean
(?SEM) concentration–time
profiles (a), and relationship
between dose and AUCinf (b).
SEM standard error of the mean
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V158866 showed a linear relationship between dose and
exposure across the entire dose range, with no evidence of
the non-linear pharmacokinetics reported for PF-04457845
[16]. The repeated dose pharmacokinetics of V158866 are
suitable for once-daily administration, with rapid absorp-
tion, a non-compartmental terminal elimination half-life in
the range 9.6–18.3 h on Day 7, and clear dose-propor-
tionality at the 7-day time point. V158866 reached steady
state Ctrough values within 2–3 days of administration, with
an accumulation ratio (at doses of 150 mg and above,
based on AUC0–24h) of about twofold on Day 7. When half-
life is estimated from the extent of accumulation in Part B,
Fig. 2 V158866 mean (?SEM)
plasma concentration–time
profiles after repeated oral
administration (Part B). Plasma
concentrations from Days 2–6
are pre-dose (Ctrough) estimates.
Ctrough lowest concentration,
SEM standard error of the mean
Table 4 Summary of V158866 pharmacokinetics on Day 1 and Day 7 of administration (Part B)
Parameter V158866 (dose/day)
50 mg (n = 6) 150 mg (n = 6) 300 mg (n = 6) 500 mg (n = 6)
Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1 Day 7













































































































Data are presented as geometric mean (geometric CV) and range unless specified otherwise
kz terminal phase apparent elimination rate constant, AUC0–24h area under the concentration–time curve from time 0–24 h, Cmax maximum
concentration, Ctrough lowest concentration, t half-life, Tmax time to maximum concentration
a Tmax is presented as median and range
b Reported plasma Ctrough values were taken approximately 24 h after administration of V158866 on Day 1 and Day 7
188 S. Pawsey et al.
the approximately twofold accumulation of V158866 is
consistent with the terminal elimination half-lives deter-
mined in Part B.
There was a tendency for the plasma concentration of
V158866 to increase between 18 and 24 h after adminis-
tration in both Part A and Part B. The reason for that is
unclear. Whilst it is possible that V158866 is subject to
enterohepatic recirculation, we would expect such a peak
in plasma concentrations to occur earlier in the PK profile
or after breakfast at 24 h. However, as faecal samples were
not collected, we have no evidence for the presence of
enterohepatic recirculation. As V158866 is more soluble at
high pH, it is also possible that further absorption of
V158866 from the large intestine occurred between 18 and
24 h after oral administration.
We had initially intended to measure the pharmacody-
namics of V158866 using two mechanistic biomarkers:
inhibition of FAAH, and changes in EC concentrations as
indicators of FAAH inhibition. However, in our hands, the
blood FAAH inhibition assay was not precise enough:
whilst it provided a clear ‘all-or-none’ marker of FAAH
inhibition (which was complete at doses of 30 mg and
above in Part A and 50 mg in Part B), it was unsuitable for
more detailed PD analysis. As V158866 acts as an inhibitor
of FAAH in blood with an IC50 (half maximal inhibitory
concentration) of *60 nM (data not shown), we relied on
Fig. 3 AEA mean (?SEM)
plasma concentrations after
single oral dose administration
(Part A). AEA N-arachidonyl
ethanolamide, SEM standard
error of the mean
Fig. 4 AEA mean (?SEM)
plasma concentrations after
repeated oral dose
administration (Part B). Plasma
concentrations from Days 2–6




error of the mean
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the measurement of plasma EC concentrations as proof of
mechanism for this study.
The effect of single oral doses of V158866 on plasma
AEA, OEA and PEA concentrations was consistent with that
of a potent, reversible FAAH inhibitor. V158866 caused
dose-related increases in plasmaAEA,OEAandPEA,which
lagged some 2 h behind the pharmacokinetic Cmax, closely
followed the changes in plasma V158866 concentrations
(including the tendency to increase between 18 and 24 h
post-dose), and returned to baseline at 72 h post-dose. This
profile is consistent with the pharmacodynamic effect being
due to parent compound rather than active metabolites. The
exception to that pattern was LEA, which showed a sec-
ondary increase in plasma concentrations in response to
V158866 (but not placebo) at the 12- and 18-h time points.
As LEA is a peripheral endocannabinoid produced in high
levels by the small intestine [22], we speculate that this may
be a local effect of V158866 in transit through the gut, on
gastrointestinal cells, resulting in a ‘pulse’ of LEA produc-
tion which is detectable in the plasma.
The counter-clockwise hysteresis loop observed in Part A
might be a result of either a requirement for V158866 to
distribute to an effect compartment, or the result of the
indirect response mechanism of V158866: in the presence of
FAAH inhibition, changes inECs becomedependent on their
rate of synthesis [23]. We have no evidence to refute either
hypothesis. Nevertheless, V158866 behaves very differently
to PF-04457845, which acts as an irreversible inhibitor of
FAAH with pharmacodynamics that outlive the presence of
the drug and are dependent on enzyme turnover to terminate
their effects [16]. In this respect, we expect V158866 to be
straightforward to dose titrate, particularly when there is a
need to reduce or terminate the effects of FAAH inhibition.
We chose to analyse the dose–response relationship of
V158866 at the Ctrough values in Part B, as this approach
allowed a concentration–response curve to be generated for
each EC at hemi-equilibrium and minimized the influence
of hysteresis [23]. V158866 caused dose-related increases
in plasma AEA, LEA, OEA and PEA concentrations, with
the plasma concentration effect best described by a sig-
moidal Emax relationship. The potency of V158866 differs
according to EC (PEA[OEA[AEA = LEA), which
appears to reflect the differential substrate specificity of
FAAH [24], and argues for the use of more than one EC as
a plasma biomarker in future studies. Nevertheless, we are
confident that V158866 is capable of inducing maximal
increases in plasma ECs for three reasons: firstly, the
relationship between plasma V158866 and EC concentra-
tions appears to reach an Emax (Fig. 5); secondly, at Day 7
of administration (Part B), further increases in plasma
V158866 from Ctrough to Cmax at 300 and 500 mg/day
(Fig. 2) cause only moderate increases in plasma AEA
(Fig. 4), and minimal changes in OEA and PEA concen-
trations, whilst LEA concentrations are doubled (electronic
supplementary material, Fig. ESM6); and thirdly, the
maximum changes in plasma AEA, LEA, OEA and PEA
concentrations (approximately 3, 4, 8 and 5 ng/mL,
respectively), are very similar to the maximum values
reported for PF-04457845 in a similar study [16].
5 Conclusions
This report summarises the first in-man study of the novel,
reversible FAAH inhibitor, V158866. V158866 had a good
tolerability profile, linear pharmacokinetics suitable for
Fig. 5 Relationship between
mean Ctrough plasma V158866
and endocannabinoid
concentrations after repeated
oral doses (Part B): the
sigmoidal Emax line of best fit is
shown for each endogenous
cannabinoid. Combined data
from all dose groups are shown;
the 24-h post-dose time point
was considered to be the Ctrough
value for each study day. AEA
N-arachidonyl ethanolamide,
Ctrough lowest concentration,
Emax maximal effect, LEA N-
linoleoyl ethanolamide, OEA N-
oleoyl ethanolamide, PEA N-
palmitoyl ethanolamide
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once-daily administration, and reversible effects on plasma
endocannabinoids. Our analysis indicates that maximum
increases in AEA, OEA and PEA occurred at plasma
V158866 concentrations of around 300 ng/mL or greater,
which were achieved with oral V158866 doses of
300–500 mg/day.
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